Bluebird Bio
Gene therapy company developing treatments for severe and incurable diseases.
Based in MA
AI Overview
With $280K in lobbying spend across 9 quarterly filings, Bluebird Bio is an active lobbying client. Their lobbying covers 2 issue areas. Active from 2019 to 2021.
Spending Trend
View as table
| Year | Lobbying Spend |
|---|---|
| 2019 | $20K |
| 2020 | $180K |
| 2021 | $80K |
Issues Lobbied
Lobbying Firms
Lobbyists
Government Agencies Targeted
These are the government entities that Bluebird Bio disclosed contacting in their lobbying filings.
What They Lobby About
These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Health Issues, Medicare/Medicaid
Issues related to developing government structures to encourage gene therapy treatment in the patient population.
Provide guidance and strategic counsel with regard to regulations and legislation that could impact the gene therapies, drug pricing, and other issues that impact the industry generally, but bluebird
Issues related to the reimbursement of gene therapies; issues related to the Patient Affordability and Efficiency Act.
S. 2543, Prescription Drug Pricing Reduction Act; issues related to value-based p
Related Analysis
Related Investigations
Similar Clients
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.